Bianchi Porro G, Parente F, Imbesi V, Montrone F, Caruso I
Department of Gastroenterology, L Sacco University Hospital, Milan, Italy.
Gut. 1996 Jul;39(1):22-6. doi: 10.1136/gut.39.1.22.
The relation between Helicobacter pylori infection and non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers remains unclear; in particular, it is not known whether H pylori plays a part in the healing and recurrence of these ulcers.
To evaluate prospectively in a consecutive series of arthritis patients receiving longterm NSAID treatment the prevalence of peptic ulcer as well as the effect of H pylori eradication on the healing and recurrence of gastric and duodenal ulcer found.
Some 278 consecutive patients underwent gastroscopy with multiple biopsies of the gastric antrum and corpus for histological examination and rapid urease test. One hundred peptic ulcers (59 gastric ulcers, 39 duodenal ulcers, and two gastric ulcers concomitant with a duodenal ulcer) were found. Seventy per cent of these ulcers were H pylori positive.
According to their H pylori status, ulcer patients were randomised to one of the following treatments: H pylori negative ulcers received omeprazole 20 mg twice daily for four to eight weeks, whereas H pylori positive lesions were treated with omeprazole 20 mg twice daily plus amoxycillin 1 g twice daily (the second of these for the first two weeks) or omeprazole alone for four to eight weeks while continuing NSAID therapy. Patients with healed ulcers were endoscopically followed up for six months after stopping antiulcer therapy while continuing NSAIDs.
Endoscopic healing rates for gastric and duodenal ulcers in the three different groups were similar both at four and eight weeks. H pylori eradication did not influence healing, which occurred in 14 of 20 (70%) of patients in whom H pylori was eradicated, compared with 14 of 17 (82%) of patients with persistent infection. Cumulative recurrence rates at six months did not statistically differ among the three different groups (27% in H pylori negative, 46% in H pylori positive, and 31% in those where H pylori was eradicated during the healing phase), although a numerical trend in favour of a higher recurrence rate in infected patients was evident.
H pylori eradication does not confer any significant advantage on the healing of gastric and duodenal ulcers associated with longterm NSAID use. It remains to be established with certainty whether eradication may be helpful in the reduction of recurrence in a specific subset of NSAID associated ulcer.
幽门螺杆菌感染与非甾体抗炎药(NSAID)相关的消化性溃疡之间的关系仍不清楚;尤其是,尚不清楚幽门螺杆菌是否在这些溃疡的愈合和复发中起作用。
前瞻性评估一系列连续接受长期NSAID治疗的关节炎患者中消化性溃疡的患病率,以及根除幽门螺杆菌对所发现的胃和十二指肠溃疡愈合及复发的影响。
约278例连续患者接受了胃镜检查,并对胃窦和胃体进行了多次活检,以进行组织学检查和快速尿素酶试验。发现100例消化性溃疡(59例胃溃疡,39例十二指肠溃疡,2例胃溃疡合并十二指肠溃疡)。这些溃疡中有70%幽门螺杆菌呈阳性。
根据幽门螺杆菌感染状况,溃疡患者被随机分为以下治疗组之一:幽门螺杆菌阴性溃疡患者每日两次服用20mg奥美拉唑,持续4至8周,而幽门螺杆菌阳性病变患者则每日两次服用20mg奥美拉唑加每日两次服用1g阿莫西林(后者在前两周服用),或仅服用奥美拉唑4至8周,同时继续NSAID治疗。溃疡愈合的患者在停止抗溃疡治疗后进行内镜随访6个月,同时继续服用NSAIDs。
在4周和8周时,三个不同组的胃和十二指肠溃疡内镜愈合率相似。根除幽门螺杆菌并不影响愈合,根除幽门螺杆菌的20例患者中有14例(70%)愈合,而持续感染的17例患者中有14例(82%)愈合。在6个月时,三个不同组的累积复发率在统计学上没有差异(幽门螺杆菌阴性组为27%,幽门螺杆菌阳性组为46%,愈合阶段根除幽门螺杆菌的组为31%),尽管有明显的数字趋势表明感染患者的复发率更高。
根除幽门螺杆菌对长期使用NSAID相关的胃和十二指肠溃疡的愈合没有任何显著优势。根除幽门螺杆菌是否有助于减少特定NSAID相关溃疡亚组的复发仍有待确定。